June 17, 2017 at 5:54 pm #94989
John Marshall, MD, and John Neil Primrose, PhD, MBBS, on Biliary Tract Cancer: Results From the BILCAP Trial.
Video discussion.June 15, 2017 at 8:45 pm #94988
The other study: Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer (ACTICCA-1)
Results should be released in 2022.
Additionally wer are awaiting data from the Chinese study gemcitabine/oxaliplatin (GEMOX) compared with capecitabine. These results are expected to be released in 2018.
MarionJune 15, 2017 at 6:55 pm #94987vtkbParticipant
The median overall survival was 15 months longer with xeloda than wothout. Not a 15 total month survival. I believe it was actually 50 months with vs 36 months without the xeloda post op. Also interesting that he spoke of another trial in europe that may compare gem/cis vs xeloda for adjuvant therapy.
-billyJune 14, 2017 at 9:58 pm #94986
Chief investigator Dr. John Primrose discuss the available data so far retrieved. More data will be analysed.
Highlights: Hilar operations are more invasive than that of intrahepatic CCA.
Some patients were not physicially able to enter this trial post surgery at 12 weeks. Study changed and integrated patients with 16 weeks post resection.
Medium Overall Survival was 15 months. Note: this is the average – some faired better others did not fair as well.
See more here:
http://www.ascopost.com/videos/2017-asco-annual-meeting/john-marshall-md-and-john-neil-primrose-phd-mbbs-on-biliary-tract-cancer-results-from-the-bilcap-trial/?utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=6714009June 7, 2017 at 5:29 pm #94972
Thanks for that Marion.June 6, 2017 at 1:48 pm #94984
More from ASCO daily news:
http://am.asco.org/post-surgery-capecitabine-should-become-standard-care-biliary-tract-cancers?j=39319004&sfmc_sub=933006565&l=18416124_HTML&u=670759436&mid=10831468&jb=13&et_cid=39319004&et_rid=933006565&linkid=Post-Surgery+Capecitabine+‘Should+Become+Standard+of+Care’+in+Biliary+Tract+CancersJune 4, 2017 at 9:54 pm #94985June 3, 2017 at 10:06 pm #94983
“These results are very intriguing. There is no current standard of care for adjuvant therapy of biliary tract cancer” says Dr. Lipika.May 19, 2017 at 7:53 pm #94982
Julie…we must believe you benefitted as well. That’s the great mystery of cancer treatment some benefit whereas others do not. Let’s see what comes out of the discussion.
MarionMay 19, 2017 at 5:25 pm #94981
Go get em Marion!!!!!May 19, 2017 at 5:14 pm #94980
While at ASCO I will have the opportunity to meet up with their team and others to discuss more details. All info will be forthcoming.
MarionMay 19, 2017 at 6:12 am #94979iowagirlMember
Thanks for posting that news. Good to read that finally something is coming from that. Now, I just would be interested in knowing if Gem /Cis given after a resection has any benefit for people like I was. I really shouldn’t look back…..what’s done is done.May 18, 2017 at 5:56 pm #94978
ASCO link here.
Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.May 18, 2017 at 5:34 pm #94977
Very big indeed Marion and the more the article is placed the better I would say!!! Hope that everyone reads it.May 18, 2017 at 4:53 pm #94976
It’s big news, Gavin. Thought to place the article here as well:
- You must be logged in to reply to this topic.